Product Center
Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-02-16
- Views:
(Summary description)Recently, Hang Seng Index Company announced the quarterly review results of the Hang Seng Index series as of December 31, 2025. Ab&B Bio-Tech Co., Ltd. (stock code: 02627.HK; hereinafter referred to as "Ab&B Bio") has successfully been included in the Hang Seng Composite Index due to its stable operating performance, standardized corporate governance, and continuously growing market value. The relevant adjustments will be implemented after the market closes on March 6, 2026 (Friday) and will take effect on March 9, 2026 (Monday). This marks a further increase in the company's coverage and recognition in the Hong Kong capital market, and a further enhancement of its influence in the international capital market. The company is also expected to be included in the scope of investable targets on the Shanghai and Shenzhen Stock Exchanges and Hong Kong Stock Connect simultaneously.
Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase
(Summary description)Recently, Hang Seng Index Company announced the quarterly review results of the Hang Seng Index series as of December 31, 2025. Ab&B Bio-Tech Co., Ltd. (stock code: 02627.HK; hereinafter referred to as "Ab&B Bio") has successfully been included in the Hang Seng Composite Index due to its stable operating performance, standardized corporate governance, and continuously growing market value. The relevant adjustments will be implemented after the market closes on March 6, 2026 (Friday) and will take effect on March 9, 2026 (Monday). This marks a further increase in the company's coverage and recognition in the Hong Kong capital market, and a further enhancement of its influence in the international capital market. The company is also expected to be included in the scope of investable targets on the Shanghai and Shenzhen Stock Exchanges and Hong Kong Stock Connect simultaneously.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-02-16 09:10
- Views:
Recently, Hang Seng Index Company announced the quarterly review results of the Hang Seng Index series as of December 31, 2025. Ab&B Bio-Tech Co., Ltd. (stock code: 02627.HK; hereinafter referred to as "Ab&B Bio") has successfully been included in the Hang Seng Composite Index due to its stable operating performance, standardized corporate governance, and continuously growing market value. The relevant adjustments will be implemented after the market closes on March 6, 2026 (Friday) and will take effect on March 9, 2026 (Monday). This marks a further increase in the company's coverage and recognition in the Hong Kong capital market, and a further enhancement of its influence in the international capital market. The company is also expected to be included in the scope of investable targets on the Shanghai and Shenzhen Stock Exchanges and Hong Kong Stock Connect simultaneously.
The Hang Seng Composite Index is one of the flagship indices of the Hong Kong stock market, covering the top 95% of the total market value of securities listed on the main board of the Hong Kong Stock Exchange. It is an important benchmark indicator reflecting the overall performance of the Hong Kong stock market. Being selected for the Hang Seng Composite Index this time means that the company meets the strict standards of Hang Seng Index companies in terms of market capitalization, liquidity level, and industry representativeness.
Recently, the company's application for the launch of the trivalent influenza virus subunit vaccine has been officially approved, jointly building a "quadrivalent+trivalent" high-end influenza vaccine product dual defense line with the company's already launched product, the quadrivalent influenza virus subunit vaccine. This accurately fits the current dual track development pattern of "more precise" and "more comprehensive" in the influenza vaccine market, and fully verifies and demonstrates the company's mature commercialization capabilities.
At the same time, the clinical trial application for the mRNA respiratory syncytial virus vaccine under development has been approved by the US Food and Drug Administration (FDA) and simultaneously accepted by the Drug Evaluation Center of the China National Medical Products Administration. This is not only another successful output of the company's mRNA technology platform, but also marks that the platform is becoming increasingly mature, laying a solid foundation for the company's continuous breakthroughs and product innovation in the field of preventive and therapeutic vaccines in the future.
In the future, the company will continue to focus on its main business, deliver sustained performance, adhere to compliant operations, and repay the trust of investors with stable performance and transparent governance.
(State Administration for Market Regulation Drug Evaluation Center Government Service Website)
(Notification email from the US Food and Drug Administration (FDA))
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
